Boxed Warning Changes on 9 HT Labels: What Changed and What Didn't

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published October 31, 2026 · Updated October 31, 2026

If you use menopause hormone therapy (HT), you may have heard that the "black box" warning is coming off. That is partly true. For nine FDA-approved hormone therapy products so far, statements about cardiovascular disease, breast cancer and probable dementia have been removed from the boxed warning. Those risks are still described elsewhere in the labels, many other HT products have not changed yet, and the boxed warning about endometrial cancer remains for systemic estrogen-alone products. Here is what changed, what is still there, and what to ask your clinician.

What is a boxed warning?

A boxed warning (often called a "black box" warning) is the most prominent safety warning FDA puts on a prescription drug label. It appears in a box at the top of the prescribing information. Removing a statement from the box does not mean a risk has gone away; it changes how prominently that risk is presented.

The timeline: from November 2025 to October 30, 2026

• November 2025. FDA asked manufacturers to change hormone therapy labels. In the boxed warning, FDA asked them to remove the language about cardiovascular diseases, breast cancer and probable dementia, and to retain the boxed warning about endometrial cancer in systemic estrogen-alone products. FDA also asked that labels keep information about cardiovascular disease and breast cancer warnings, and that they add consideration of starting hormone therapy for moderate to severe hot flashes in women under 60 or within 10 years of menopause.
• February 12, 2026. FDA approved the first label changes, for six products spanning four categories: systemic combination therapy, systemic estrogen-alone therapy, progestogen-alone therapy and topical vaginal estrogen. FDA said 29 drug companies had submitted proposed labeling changes.
• October 30, 2026. FDA approved updated labels for three more products, all estradiol transdermal patches from two applicants. FDA's product list, updated Oct 30, now names Minivelle, Vivelle and Vivelle-Dot among the systemic estrogen-alone products with updated prescribing information. That brings FDA's list to nine products. See FDA's full list.

What is still in the label

• The risks are still described. FDA asked that labels retain information about cardiovascular disease and breast cancer warnings. Removing statements from the box moves the emphasis; it does not remove the risk information.
• The endometrial cancer boxed warning stays for systemic estrogen-alone products. Estrogen taken without a progestogen raises the risk of uterine (endometrial) cancer in people who have a uterus. Minivelle, Vivelle and Vivelle-Dot are estrogen-alone patches.
• Not every HT product has changed. FDA says it is still working with manufacturers on the remaining products, so the label for your product may still carry the older boxed warning. To date, 29 companies have submitted proposed labeling changes, according to HHS. Generic versions may not be updated yet.
• Check your own product's label. Updated labels can take time to appear online. As of Oct 31, 2026, the DailyMed pages for Minivelle and Vivelle-Dot (listed in Sources) still showed the earlier boxed warning. Ask your pharmacist for the current prescribing information for the exact product you use.

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. For the most current list of updated labels, see FDA's updated prescribing information page. Labels on DailyMed and on pharmacy printouts can lag behind FDA approvals, so ask your pharmacist for the current prescribing information for your exact product, and talk with your clinician about risks and benefits.

"Under 60 or within 10 years of menopause": what it means, and what's still debated

FDA's November 2025 request asked labels to add consideration of starting hormone therapy for moderate to severe hot flashes in women under 60 or within 10 years of menopause. At the Oct 30 briefing, an FDA official said that for many healthy women in that group, the risk-benefit profile "looks meaningfully different than older warnings conveyed," according to The Guardian. The Menopause Society's November 2025 statement said risks are low for younger, healthy women starting hormone therapy closer to the menopause transition, and greater when started in older women and those further from menopause onset. It added that systemic estrogen still comes with potential risks in certain individuals.

Experts have also raised open questions:

• Starting later. Susan Reed, MD, of UW Medicine, told Contemporary OB/GYN that questions to consider include whether these products are safe when started over ages 60 to 65.
• Patches with oral progestogens. Reed also asked whether labels should mention risks when transdermal estrogen is taken with an oral progestogen. (People with a uterus generally need a progestogen alongside estrogen.)
• No advisory committee. The Guardian reported that FDA did not convene an advisory committee for the Oct 30 decision and that officials said the evidence could be provided later. An FDA official said the older warnings had painted a broad and, in some cases, overstated picture of risk.

These are open questions, not settled answers. Your age, time since menopause, whether you have a uterus, and your personal and family history all matter.

Questions to ask your clinician

• Has the label for my specific product changed, and what does it say now?
• Given my age, time since menopause and health history, how do the benefits and risks look for me?
• I have a uterus: what progestogen do I need with estrogen, and in what form?
• Would a patch, gel, spray or pill make a difference for me?
• How often should we review whether I should continue?

Prescriptions, when appropriate, are issued by licensed clinicians.

If you can't find your patch

In its Oct 30, 2026 announcement, HHS said FDA, based on current information, is not aware of an imminent risk of a nationwide shortage, and that it continues to work with all six manufacturers of FDA-approved estradiol patches. HHS said overall patch market output has doubled in the last 12 months, and that availability can vary by brand, strength, once-weekly or twice-weekly schedule and location. FDA also said patches are only one option and that it is monitoring supply of other forms, such as gels and creams.

• Ask your pharmacist to check other locations, or another FDA-approved estradiol patch that can be substituted when appropriate.
• Talk with your clinician before switching products, strengths or schedules.
• Do not stop or change your medication on your own, and do not cut, double up or stretch patches.

Your pharmacist and clinician can help you find an option that works for you.

Over-the-counter vaginal estrogen: not available yet

HHS said FDA is working with sponsors to explore whether vaginal estrogen products could be sold over the counter. This is only being explored: vaginal estrogen still requires a prescription, and any switch would need FDA approval based on evidence that people can choose and use the product safely without a clinician.

To learn more about who we are, see about Kindr Health.

Interested in menopause care? Learn about menopause care at Kindr Health. Treatment options vary by state and clinical eligibility.

Sources: HHS, "Trump Administration Delivers for Women with Major Advances in Menopause Care" (Oct 30, 2026); FDA, "Menopausal Hormone Therapies with Updated Prescribing Information" (updated Oct 30, 2026); FDA, "FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies" (Nov 2025); FDA, "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products" (Feb 12, 2026); The Guardian (Oct 30, 2026); Contemporary OB/GYN (Oct 30, 2026); The Menopause Society (Nov 10, 2025); DailyMed, Minivelle (label shown may predate Oct 30 update); DailyMed, Vivelle-Dot (label shown may predate Oct 30 update).

This article is for educational purposes only and is not medical advice. It does not replace a consultation with a licensed healthcare professional. Talk with your clinician before starting, stopping or changing any treatment. See our full medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: October 31, 2026